Rhythm Pharmaceuticals, Inc. on August 4, 2023 notified William T. Roberts, the Company?s Chief Accounting Officer, of the termination of Mr. Roberts? employment with the Company, to be effective on August 11, 2023. On August 8, 2023, the Board of Directors of the Company designated Christopher German, the Company?s Executive Director, Corporate Controller, as principal accounting officer, effective on the Effective Date.

Mr. German, 52, has served as Executive Director, Corporate Controller since March 2023. Mr. German brings over 20 years? experience in financial reporting, accounting, treasury and audit from global, publicly-traded life sciences, technology and manufacturing companies.

He joined Rhythm from Oncorus, Inc., a biopharmaceutical company, where he served as Corporate Controller from May 2021 to March 2023. Prior to that, Mr. German served as Corporate Controller at Repligen Corporation from July 2018 to March 2021, and held various senior accounting positions at Seachange International, Inc. from September 2016 to July 2018. Mr. German holds a B.S. in Accounting from Lehigh University and is a Certified Public Accountant.